Qiong Wu, Yuxiang Liu, Qingqing Chen and Xiaoyi Zhuang of Haiwen & Partners provide essential insights into an essential new judicial interpretation concerning labor dispute cases, including a comparison with the current rules and judicial practice and implications for compliance and risk management practices
Court interpretation of rules governing mandatory social insurance payments causes backlash; Proposed changes to implementation of China’s VAT regime aim to clarify gray areas; and Arkansas joins push to divest pension funds from China.
Eric (Ye) Zou of Merits & Tree Law Offices gives an overview of the core elements and key significance of a new pilot scheme which maps out a new way for foreign investors to access China’s flourishing financial markets
In the first part of a series of articles, Jianwei (Jerry) Fang, Ke Dong, and Haoyi Sun of Zhong Lun Law Firm outline the general jurisdiction rules governing foreign-related civil litigation in China under the 2024 Civil Procedure Law, and explain the statutory framework, key jurisdictional bases, and procedural considerations that foreign companies and in-house counsel need to understand when facing potential lawsuits in Chinese courts
FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
Daisy Duan, Xiaohong Chen, Cuishi Li of KWM examine a new tax credit policy which is aimed at boosting profit reinvestment by foreign investors
STA offers substantive tax deduction incentives to foreign investors / CLP Reference: 3230/25.01.27 ; Issued: 2025-06-27 ; Effective: from 2025-01-01 to 2028-12-31
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
Chinese EV giant BYD investigated in U.S. for alleged ties to Chinese Communist Party; European companies more pessimistic about doing business in China amid economic slowdown; and the world’s first intergovernmental legal organization for mediation established in Hong Kong
